Anderson, M;
Drummond, M;
Taylor, D;
McGuire, A;
Carter, P;
Mossialos, E;
(2022)
Promoting innovation while controlling cost: The UK's approach to health technology assessment.
Health Policy
10.1016/j.healthpol.2022.01.013.
(In press).
Preview |
Text
1-s2.0-S0168851022000239-main.pdf - Published Version Download (556kB) | Preview |
Abstract
New technologies, including pharmaceuticals and medical devices, can improve treatment options in healthcare but also bring concerns about rising healthcare costs. We undertake a narrative review of the United Kingdom's (UK) approach to appraising new health technologies. We find that the National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC) and All Wales Medicines Strategy Group (AWMSG) have contributed to the UK's robust and transparent approach towards the evaluation of new health technologies using the cost per QALY approach. However, there are limitations to this approach including several external benefits not captured, bias against less treatable diseases, and deciding the appropriate level of the threshold. NICE, SMC, and AWMSG have attempted to overcome some of these limitations by considering additional factors such as end-of-life criteria, highly specialised treatments, and populations that experience unmet need. Looking to the future, the advent of ‘personalised’ and ‘genomic’ medicine, will likely mean the UK has to accommodate an increasing number of ‘step-change’ and ‘highly specialised’ technologies as well as respond to changes in pharmaceutical licensing and increasing use of real-world evidence.
| Type: | Article |
|---|---|
| Title: | Promoting innovation while controlling cost: The UK's approach to health technology assessment |
| Location: | Ireland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.healthpol.2022.01.013 |
| Publisher version: | https://doi.org/10.1016/j.healthpol.2022.01.013 |
| Language: | English |
| Additional information: | © 2022 The Authors. Published by Elsevier B.V. under a Creative Commons license (https://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Health technology assessment, Medicines, Pharmaceuticals, QALY, Quality adjusted life year, United kingdom |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10144261 |
Archive Staff Only
 |
View Item |
